CSL (CSLLY) and Arcturus Therapeutics (ARCT) announced the publication in Lancet Infectious Diseases of a Phase 3 study showing that a booster dose of ARCT-154, a novel, self-amplifying messenger RNA, or sa-mRNA, vaccine, elicited a numerically higher immune response against the original Wuhan-Hu-1 virus strain, and a superior immune response against Omicron BA.4/5 subvariant of SARS-CoV-2 virus compared to a booster dose of the conventional mRNA vaccine Comirnaty. ARCT-154 results were achieved with one sixth the dose of Comirnaty. The study included healthy adults initially immunized with two doses of an mRNA vaccine; and then a third dose of Comirnaty at least three months prior to the booster dose of either ARCT-154 or Comirnaty in the study. Both vaccines were well-tolerated, with no causally associated severe or serious adverse events. The study was conducted in partnership with Meiji Seika Pharma, a global health company based in Japan.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ARCT:
- Arcturus Therapeutics initiated with bullish view at Canaccord, here’s why
- Arcturus Therapeutics initiated with bullish view at Canaccord
- Arcturus Therapeutics price target raised to $60 from $51 at H.C. Wainwright
- CSL’s and Arcturus Therapeutics’ mRNA vaccine for COVID approved in Japan
- Arcturus Therapeutics receives Orphan Drug Designation for ARCT-032 from FDA
